Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

High value applications

Hovione provides off-patent APIs that can be used with confidence where the choice of active ingredient is critical.

Page
Read more

60 Years

In 2019, Hovione celebrates its 60th Anniversary.

Page
Read more

Regulatory Affairs

Hovione has filings with every world health authority that has a DMF system for APIs including FDA EDQM PMDA,MHRA, HPRA, Infarmed among others.

Page
Read more